A new study from the Institute of Science and Technology Austria (ISTA) introduces a brain organoid model that includes microglia, the brain’s immune cells. This addition enhances the model’s ability to simulate inflammation and improves prospects for safer pharmaceutical testing during pregnancy. The development is timely for global health and aligns with Thai prenatal care policy ambitions to refine safe medication guidelines for expectant mothers.
Historically, brain organoid models lacked microglia, limiting their accuracy in mimicking how the human brain responds to infections. By incorporating microglia, researchers can better understand how the developing nervous system reacts to infections such as Rubella, a concern for pregnant women due to potential fetal complications. In Thailand, where maternal and neonatal health remains a policy priority, this research supports national efforts to reduce congenital risks and strengthen prenatal care.
Researchers used human-induced pluripotent stem cells to grow retinal organoids and successfully integrated microglia, enabling a fuller representation of early brain development. The team—led by doctoral researcher Verena Schmied with Professor Sandra Siegert—published their findings in the Journal of Neuroinflammation. The work highlights the dynamic interaction between neurons and microglia when challenged by viral components, underscoring microglia’s central role in shaping developmental outcomes during infections.
In experiments where a synthetic viral molecule was introduced, microglia initiated inflammation. This inflammatory cascade could hinder neuron formation and disrupt developing neural networks, illustrating the important influence microglia have on neurodevelopment under infectious stress. The model’s ability to reflect these inflammatory processes strengthens its value for evaluating potential therapies and safety.
A key insight from the study is the impact of ibuprofen on inflammation-driven neuronal disruption. The research showed that ibuprofen could mitigate such disruptions, but its effectiveness depended on the presence of microglia. This nuance emphasizes the importance of including microglia in organoid models for realistic drug testing. With ongoing questions about the safety of anti-inflammatory medications during pregnancy, the findings add a crucial layer of evidence for policymakers and clinicians.
For Thailand, adopting advanced organoid models could bolster local drug testing and prenatal care frameworks. As Thai health authorities pursue improvements in maternal and fetal health outcomes, understanding how viral infections affect fetal development through enhanced models can inform safer medication guidelines and preventive strategies. Advancing organoid technologies could elevate Thailand’s scientific profile and encourage international collaboration.
Looking ahead, these models offer potential beyond Rubella and ibuprofen. They can support research into various neurodevelopmental conditions relevant to Thailand’s health priorities. Developing similar capabilities domestically would empower Thai researchers to contribute to global medical science while addressing national needs.
Thai readers and healthcare professionals are encouraged to follow organoid research developments and consider policy updates that reflect these advances. A deeper understanding of medication safety during pregnancy, informed by robust organoid models, could help shape safer guidelines for expectant mothers.